Evaluation of the Safety of Adjuvant Capecitabine Regimen for Stages II Colon Cancer

Abstract

Objective: Evaluate the safety of adjuvant capecitabine regimens for stage II colorectal cancer patients at K Hospital. Methods: A retrospective descriptive study in 96 stage II colon cancer patients according to AJCC 2017 were treated with radical surgery and adjuvant treatment with capecitabine regiments at K Hospital from January 2016 to December 2019. Side effects of chemotherapy regimens were identified. Results: 93 patients completed all 8 cycles of chemotherapy, accounting for 96.8%. The majority experienced grade 1 and grade 2 toxicities at approximately 50%. Grade 3 toxicity had a low incidence rate of <5% and there were no grade 4 toxicities. Common toxicities included hand-foot syndrome (51%), anemia (30.2%), and diarrhea (10.4%). The rate of treatment delays or dose reductions due to toxicity was only 4% and no patients discontinued treatment due to toxicity. Conclusion: Adjuvant capecitabine regimens for stage II colorectal cancer were well tolerated.